VENADO bone graft systems launched by K2M

K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company’s U.S. biologics offering with the launch of the VENADO^® Foam Strips and VENADO Granules Bone Graft Systems. 

VENADO represents an entirely new product family in K2M’s growing biologics portfolio, already featuring VIKOS® Allograft Systems and VESUVIUSTM Osteobiologic Systems. The systems are available in a variety of configurations and sizes specifically designed to enhance bone regeneration and act as an osteogenic stimulus after spine surgery. VENADO Foam Strips are purified fibrillar collagen and biphasic granules. The Foam Strips hydrate quickly in blood or saline, and become very flexible and moldable, yet are less likely to dissociate or break apart. When bone cells migrate into the graft composite, the implant functions as a scaffold for osteogenic components. VENADO Granules are a biphasic combination of hydroxyapatite and beta-tricalcium phosphate with excellent resorption characteristics.  

According to Dr. Faheem Sandhu, neurosurgeon and Associate Professor at Georgetown University Hospital, “VENADO provides for synthetic bone graft alternatives for hospitals and surgeons interested in a non-allograft solution to the management of complex spinal surgical issues, and these unique products complement and enhance K2M’s already comprehensive and innovative spine portfolio.”

“We are excited to bring to market the VENADO Bone Graft Systems and to expand on our company’s presence in the rapidly growing biologics sector,” stated Eric Major, K2M’s President and CEO. “The launch of VENADO enables us to meet a significant demand for the high quality products surgeons have come to expect from K2M.”

About K2M

K2M, Inc. is the largest privately held spinal device company in the world focused on the research, development, and commercialization of innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures.  The company is recognized as a global leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients.  K2M’s product development pipeline includes: spinal stabilization systems, minimally invasive systems, biologics, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement.  Additional information is available online at www.K2M.com.

Find K2M on Facebook: https://www.facebook.com/K2MInc

Follow K2M on Twitter: https://twitter.com/K2MInc

Watch K2M on YouTube: https://www.youtube.com/user/K2MInc